Nurix Extends Gilead Collaboration For Oncology Program

By Reuters News

- Nurix Therapeutics, Inc. NRIX.O:

  • NURIX THERAPEUTICS ANNOUNCES SECOND RESEARCH TERM EXTENSION FOR ONCOLOGY PROGRAM UNDER COLLABORATION WITH GILEAD SCIENCES

  • NURIX - CO AND GILEAD EXTEND ONCOLOGY PROGRAM RESEARCH TERM BY TWO YEARS

  • NURIX - RETAINS CO-DEVELOPMENT AND 50/50 PROFIT SHARING OPTIONS ON TWO U.S. PROGRAMS

  • NURIX - TO RECEIVE $10 MILLION RESEARCH TERM EXTENSION FEE

  • NURIX - ELIGIBLE FOR UP TO $1.30 BILLION IN TOTAL PAYMENTS AS OF MAY 31, 2026

  • NURIX - ELIGIBLE FOR MID-SINGLE-DIGIT TO LOW-TEENS PERCENTAGE TIERED ROYALTIES

Further company coverage: NRIX.O

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk